Bipolar Disorder in Pregnancy and Postpartum: Principles of Management

Current Psychiatry Reports

Volumn 18, Issue 2, 2016, Pages 1-11

  Khan, Sabrina J ^a   Fersh, Madeleine E ^b   Ernst, Carrie ^c   Klipstein, Kim ^c,d,e   Albertini, Elizabeth Streicker ^c   Lusskin, Shari I ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI HEALTH SYSTEM   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Bipolar disorder; Depression; Lactation; Mood stabilizers; Neonatal complications; Neurodevelopmental effects; Perinatal; Postpartum; Pregnancy; Teratogenicity

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FOLIC ACID; LAMOTRIGINE; LITHIUM; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; LITHIUM DERIVATIVE; TRIAZINE DERIVATIVE;

BIPOLAR DISORDER; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; ELECTROCONVULSIVE THERAPY; HUMAN; LACTATION; MATERNAL CARE; NERVE CELL DIFFERENTIATION; ORAL CONTRACEPTIVE USE; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PUERPERIUM; RELAPSE; REVIEW; RISK ASSESSMENT; SCREENING TEST; TREATMENT OUTCOME; TREATMENT PLANNING; FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS; RISK;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; LACTATION; LITHIUM COMPOUNDS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; RISK; TRIAZINES; VALPROIC ACID;

EID: 84958160754     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-015-0658-x     Document Type: Review

References (78)

1. Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet. 2014;384(9956):1789–99. doi:10.1016/s0140-6736(14)61278-2.
2. Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002;63(4):284–7.
3. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24. doi:10.1176/appi.ajp.2007.06101639.
4. Sharma V, Burt VK, Ritchie HL. Bipolar II postpartum depression: detection, diagnosis, and treatment. Am J Psychiatry. 2009;166(11):1217–21. doi:10.1176/appi.ajp.2009.08121902.
5. Frey BN, Simpson W, Wright L, Steiner M. Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period. J Clin Psychiatry. 2012;73(11):1456–61. doi:10.4088/JCP.12m07856.
6. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118 Suppl 1:1–203. doi:10.1111/j.1471-0528.2010.02847.x.
7. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157(2):179–84.
8. Bergink V, Armangue T, Titulaer MJ, Markx S, Dalmau J, Kushner SA. Autoimmune encephalitis in postpartum psychosis. Am J Psychiatry. 2015:appiajp201514101332. doi:10.1176/appi.ajp.2015.14101332.
9. Merrill L, Mittal L, Nicoloro J, Caiozzo C, Maciejewski PK, Miller LJ. Screening for bipolar disorder during pregnancy. Arch Womens Ment Health. 2015;18(4):579–83. doi:10.1007/s00737-015-0527-y.
10. Chessick CA, Dimidjian S. Screening for bipolar disorder during pregnancy and the postpartum period. Arch Womens Ment Health. 2010;13(3):233–48. doi:10.1007/s00737-010-0151-9.
11. Sharma V, Xie B. Screening for postpartum bipolar disorder: validation of the Mood Disorder Questionnaire. J Affect Disord. 2011;131(1–3):408–11. doi:10.1016/j.jad.2010.11.026.
12. Sharma V, Pope CJ. Pregnancy and bipolar disorder: a systematic review. J Clin Psychiatry. 2012;73(11):1447–55. doi:10.4088/JCP.11r07499.
13. March of Dimes Foundation. Quick facts: birth defects. 2013 [8/5/15]; Available from: http://www.marchofdimes.com/peristats/ViewTopic.aspx?reg=99&top=16&lev=0&slev=1&dv=mt.
14. Boden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345, e7085. doi:10.1136/bmj.e7085.
15. Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161(4):608–20.
16. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatr. 2005;162(11):2162–70.
17. Nora JJ, Nora AH, Toews WH. Letter: Lithium, Ebstein’s anomaly, and other congenital heart defects. Lancet. 1974;2(7880):594–5.
18. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium.[see comment][erratum appears in JAMA 1994 May 18;271(19):1485]. JAMA. 1994;271(2):146–50.
19. Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171(7):785–94. doi:10.1176/appi.ajp.2014.12111402. This is a prospective, comparative observational study evaluating the risk of major malformations associated with lithium exposure during pregnancy. Lithium exposure was associated with an increased rate of cardiovascular anomalies (5/123 [4.1%] compared with 4/711 [0.6%] in the non-teratogenic exposure group), however this risk was no longer statistically significant after excluding malformations which resolved spontaneously.
20. Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature. Am J Med Genet A. 2005;132A(4):441–4. doi:10.1002/ajmg.a.30501.
21. van der Lugt NM, van de Maat JS, van Kamp IL, Knoppert-van der Klein EA, Hovens JG, Walther FJ. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev. 2012;88(6):375–8. doi:10.1016/j.earlhumdev.2011.09.013. This observational retrospective cohort study evaluated the growth and neurodevelopment of 15 children exposed to lithium in pregnancy at 3–15 years and found that lithium exposure was not associated with adverse effects on growth and cognitive development.
22. Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014;34(2):244–55. doi:10.1097/jcp.0000000000000087. This paper reviews the pharmacokinetic changes of antidepressants and mood stabilizers during pregnancy, discusses the implications for clinical and therapeutic drug monitoring, and offers clinical recommendations.
23. Bergink V, Kushner SA. Lithium during pregnancy. Am J Psychiatry. 2014;171(7):712–5. doi:10.1176/appi.ajp.2014.14030409.
24. Viguera AC, Newport D, Ritchie J, Stowe Z, Whitfield T, Mogielnicki J, et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry. 2007;164(2):342–5.
25. Marin Gabriel MA, Olza Fernandez I, Donoso E, Gutierrez Cruz N. Lithium and artificial breastmilk; or is maternal breastfeeding better? An Pediatr (Barc). 2011;75(1):67–8. doi:10.1016/j.anpedi.2010.12.007.
26. Bogen DL, Sit D, Genovese A, Wisner KL. Three cases of lithium exposure and exclusive breastfeeding. Arch Womens Ment Health. 2012;15(1):69–72. doi:10.1007/s00737-012-0257-3.
27. Tomson T, Battino D. Antiepileptic treatment in pregnant women: morphological and behavioural effects. Handb Exp Pharmacol. 2011;205:295–315. doi:10.1007/978-3-642-20195-0_15.
28. Werler MM, Ahrens KA, Bosco JL, Mitchell AA, Anderka MT, Gilboa SM, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011;21(11):842–50. doi:10.1016/j.annepidem.2011.08.002.
29. Mawhinney E, Campbell J, Craig J, Russell A, Smithson W, Parsons L, et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important? Seizure. 2012;21(3):215–8. doi:10.1016/j.seizure.2012.01.005.
30. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC, Group NS. In utero antiepileptic drug exposure: fetal death and malformations.[see comment]. Neurology. 2006;67(3):407–12.
31. Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–9. doi:10.1212/WNL.0b013e3182574f39.
32. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs. 2008;22(4):325–34.
33. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17. doi:10.1016/S1474-4422(11)70107-7.
34. Vajda FJ, O'Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013;81(11):999–1003. doi:10.1212/WNL.0b013e3182a43e81.
35. Ozkan H, Cetinkaya M, Koksal N, Yapici S. Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med. 2011;24(3):521–4. doi:10.3109/14767058.2010.501120.
36. Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–703. doi:10.1001/jama.2013.2270. This Danish population based study found that prenatal exposure to valproate was associated with an increased risk of autism spectrum disorder and childhood autism; the 508 children exposed to valproate had an absolute risk of 4.42 % (95 % CI, 2.59–7.46 %) for autism spectrum disorder (adjusted HR, 2.9 [95 % CI, 1.7–4.9]) and an absolute risk of 2.50 % (95 % CI, 1.30–4.81 %) for childhood autism (adjusted HR, 5.2 [95 % CI, 2.7–10.0]).
37. FDA. Valproate sodium and related products (valproic acid and divalproex sodium): risk of birth defects: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm192788.htm [released 12/3/09]. 2009 [8/14/15].
38. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22.
39. Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305(19):1996–2002. doi:10.1001/jama.2011.624.
40. Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029–34. doi:10.1136/jnnp-2013-306318.
41. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261(3):579–88. doi:10.1007/s00415-013-7239-x.
42. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–52. doi:10.1016/s1474-4422(12)70323-x.
43. Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, Garcia-Finana M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015;84(4):382–90. doi:10.1212/wnl.0000000000001182.
44. Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;10, Cd010236. doi:10.1002/14651858.CD010236.pub2.
45. Veiby G, Daltveit AK, Schjolberg S, Stoltenberg C, Oyen AS, Vollset SE, et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013;54(8):1462–72. doi:10.1111/epi.12226.
46. Paulzen M, Lammertz SE, Veselinovic T, Goecke TW, Hiemke C, Grunder G. Lamotrigine in pregnancy—therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol. 2015;30(5):249–54. doi:10.1097/yic.0000000000000088. This study measured lamotrigine concentrations in maternal blood, amniotic fluid, and umbilical cord blood in six mother-infant pairs at delivery. Lamotrigine levels in serum were strongly correlated with the lamotrigine levels in the amniotic fluid and cord blood.
47. Kacirova I, Grundmann M, Brozmanova H. Serum levels of lamotrigine during delivery in mothers and their infants. Epilepsy Res. 2010;91(2–3):161–5. doi:10.1016/j.eplepsyres.2010.07.007.
48. Fotopoulou C, Kretz R, Bauer S, Schefold JC, Schmitz B, Dudenhausen J, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009;85(1):60–4.
49. Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):142–9. doi:10.1212/WNL.0b013e3181a6b325.
50. Newport DJ, Stowe ZN, Viguera AC, Calamaras MR, Juric S, Knight B, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord. 2008;10(3):432–6. doi:10.1111/j.1399-5618.2007.00565.x.
51. Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170(11):1240–7. doi:10.1176/appi.ajp.2013.13010006.
52. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41(6):709–13.
53. Page-Sharp M, Kristensen JH, Hackett LP, Beran RG, Rampono J, Hale TW, et al. Transfer of lamotrigine into breast milk. Ann Pharmacother. 2006;40(7–8):1470–1.
54. Wakil L, Epperson CN, Gonzalez J, O'Reardon JP, Kim DR. Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. Psychopharmacol Bull. 2009;42(3):91–8.
55. Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013;70(11):1367–74. doi:10.1001/jamaneurol.2013.4290.
56. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology. 2010;75(22):1954–60. doi:10.1212/WNL.0b013e3181ffe4a9.
57. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168(8):729–36. doi:10.1001/jamapediatrics.2014.118.
58. Veiby G, Bjork M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. Seizure. 2015;28:57–65. doi:10.1016/j.seizure.2015.02.013.
59. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47(1–2):151–4.
60. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61(4):570–1.
61. Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48(3):484–9. doi:10.1111/j.1528-1167.2007.00997.x.
62. Vigod SN, Gomes T, Wilton AS, Taylor VH, Ray JG. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298. doi:10.1136/bmj.h2298.
63. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.[see comment]. Journal of Clinical Psychiatry. 2005;66(4):444–9; quiz 546.
64. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279–88. doi:10.1097/JCP.0b013e318172b8d5.
65. Habermann F, Fritzsche J, Fuhlbruck F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–62. doi:10.1097/JCP.0b013e318295fe12.
66. Kulkarni J, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9(5), e94788. doi:10.1371/journal.pone.0094788.
67. Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2014. doi:10.1111/bcpt.12372. A literature review of the available data on the risk of malformations with first-trimester exposure to the newer antipsychotics: olanzapine, quetiapine, risperidone and aripiprazole. The rate of malformation was 3.5 % for olanzapine, 3.6 % with quetiapine, and 5.1 % with risperidone; data for aripiprazole was limited.
68. Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125(5):1224–35. doi:10.1097/aog.0000000000000759.
69. Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715–21. doi:10.1001/archgenpsychiatry.2011.1870.
70. Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2015;35(5):559–65. doi:10.1097/JCP.0000000000000391.
71. FDA. FDA Drug Safety Communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm [released 2/22/2011]. 2011 [8/14/15].
72. Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69(8):787–94. doi:10.1001/archgenpsychiatry.2012.160.
73. Peng M, Gao K, Ding Y, Ou J, Calabrese JR, Wu R, et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berlin). 2013. doi:10.1007/s00213-013-3060-6.
74. Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–20.
75. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114(3):703–13. doi:10.1097/AOG.0b013e3181ba0632.
76. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Commun Psychiatry. 1994;45(May):444–50.
77. Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med. 2009;71(2):235–42. doi:10.1097/PSY.0b013e318190d7ca.
78. Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Hoie B. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Womens Ment Health. 2015;18(1):1–39. doi:10.1007/s00737-013-0389-0.